Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: A novel small molecule glycolysis inhibitor WZ35 exerts anti-cancer effect via metabolic reprogramming

Fig. 1

YAP upregulation in liver cancer cells corresponds to the poorer patient outcomes. A Volcano map of RNA-seq data from GEO database visualizing differentially expressed genes (DEGs) between the tumor samples and the normal ones with gene YAP1 marked out (Fold change of > 0.5 and adjusted P < 0.05). B Box plot exhibits the distinct expression of YAP1 in the normal and the tumor samples, with the blue box is representative of the tumor samples and the red box of the normal samples. C Western blotting shows differential expression of YAP in the normal and the tumor tissues. D and E YAP IHC staining in liver cancer patient samples. Representative YAP-stained images of normal, TNM stage I, II, III and IV tumor tissues have been shown and quantified. F Kaplan–Meier approach visualized the relationship between YAP expression and OS in liver cancer patients (n = 110, P < 0.01)

Back to article page